On 31 March 2026, the Agency transmitted to the Commission the revised summary of the product characteristics of the Union authorisation for the biocidal product family ‘LANXESS CMIT/MIT biocidal product family’ in all official languages of the Union, covering all the administrative changes and minor changes notified and applied for, in accordance with Article 11(6) and Article 12(6) of Implementing Regulation (EU) No 354/2013.
Recital 7, Regulation (EU) 2026/2024
In forcesince 10 Sep 2026